Search

Your search keyword '"Kim, Sung Hyun"' showing total 4,071 results

Search Constraints

Start Over You searched for: Author "Kim, Sung Hyun" Remove constraint Author: "Kim, Sung Hyun"
4,071 results on '"Kim, Sung Hyun"'

Search Results

211. Efficiency Improvement of Energy Harvesting Device Using Light Pressure Through Plasmon Coupling at the Interface Between Grained Ag Layer and Au Nanoparticles.

212. Simultaneous control of mechanical strength and hierarchical structure in freeze‐casted porous alumina by two‐step sintering.

214. Enhancing thermoelectric performance of single-walled carbon nanotube/reduced graphene oxide composites with small organic molecules as a novel additive.

215. Diversity of Cladosporium (Cladosporiales, Cladosporiaceae) species in marine environments and report on five new species

222. Rhein Induces Oral Cancer Cell Apoptosis and ROS via Suppresse AKT/mTOR Signaling Pathway In Vitro and In Vivo

225. Supplementary Table Legend from Direct Targeting of MEK1/2 and RSK2 by Silybin Induces Cell-Cycle Arrest and Inhibits Melanoma Cell Growth

226. Supplementary Table 1 from Direct Targeting of MEK1/2 and RSK2 by Silybin Induces Cell-Cycle Arrest and Inhibits Melanoma Cell Growth

227. Supplementary Figure 1 from Direct Targeting of MEK1/2 and RSK2 by Silybin Induces Cell-Cycle Arrest and Inhibits Melanoma Cell Growth

228. Supplementary Figure 2 from Direct Targeting of MEK1/2 and RSK2 by Silybin Induces Cell-Cycle Arrest and Inhibits Melanoma Cell Growth

230. Supplementary Figure Legend from Direct Targeting of MEK1/2 and RSK2 by Silybin Induces Cell-Cycle Arrest and Inhibits Melanoma Cell Growth

231. Supplementary Methods, Supplementary Figure Legends, Supplementary Table from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

232. Supplementary Figure 1C from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

233. Supplementary Data from Prediction of Recurrence-Free Survival in Postoperative Non–Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression

234. Supplementary Figure 3B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

235. Supplementary Figure 2 from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

236. Data from Prediction of Recurrence-Free Survival in Postoperative Non–Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression

237. Supplemental Figure 5 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

238. Data from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

239. Supplemental Table 1 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

240. Supplemental Figure 2 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

241. Supplemental Figure 10 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

242. Supplemental Figure 4 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

243. Supplemental Figure 9 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

244. Supplemental Figure 3 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

245. Supplemental Figure 6 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

246. Supplemental Figure Legend from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

247. Supplemental Materials and Methods from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

248. Supplemental Figure 8 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

249. Supplemental Figure 7 from Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity

Catalog

Books, media, physical & digital resources